Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

NCT05470504 | Recruiting Phase 2 FDA Drug

• 2 other identifiers: 10000756000756-DK
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems. Objective: To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance. Eligibility: Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD. Design: Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights. During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue. During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home. After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests. Participants will stop the shots after the second hospital visit.

Conditions

Partial Lipodystrophy; Insulin Receptor Mutation

Keywords

Pegvisomant; Severe Insulin Resistance; Growth Hormone Inhibition; LIPOLYSIS

Outcome Measures

Primary Outcomes (1)

• Glycerol rate of appearance (Ra) normalized to fat mass, Palmitate Ra normalized to fat mass

  Estimate the magnitude and variability of the effect of pegvisomant, 30 mg subcutaneously once daily for 1 month, on adipose tissue lipolysis rate in subjects with pathogenic variants in the insulin receptor and partial lipodystrophy.

  1 month

Study Arms (1)

1

OTHER

open label pegvisomant

Drug: Pegvisomant

Interventions

Pegvisomant DRUG

30 mg subcutaneously every day for 4 weeks.

1

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be eligible to participate in this study, an individual must meet all the following criteria:
• Either
• Known pathogenic variant in the insulin receptor gene, either dominant negative or recessive, OR
• Clinical diagnosis of partial lipodystrophy based on reduction in adipose tissue outside the normal range in selected adipose depots (including, at a minimum, the gluteofemoral depot) with preservation of adipose tissue in other depots.
• Male or female, aged 18-70 years.
• Completed linear growth and puberty.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Use of niacin or other drugs that directly affect lipolysis within 8 weeks prior to enrollment.
• Patients taking anticoagulants (blood thinning medications).
• Use of non-steroidal anti-inflammatory medications (e.g., aspirin, ibuprofen) 2 weeks prior to the biopsy date (in patients who choose to undergo biopsy).
• Changes in medications for diabetes or dyslipidemia within 2 weeks prior to enrollment.
• Pregnancy or lactation.
• For females of reproductive potential: inability or unwillingness to use contraception during study participation and for an additional 1 month after the end of pegvisomant administration.
• For males of reproductive potential: inability or unwillingness to use condoms or other methods to ensure effective contraception with partner during the study and for an additional 1 month after the end of pegvisomant administration.
• Known allergic reactions pegvisomant or any of its components.
• Clinically significant liver disease, evidenced by any of the following:
• ALT or AST \>3 times the upper limit of normal at screening.
• Current known liver disease other than steatohepatitis (e.g., autoimmune or viral hepatitis).
• History of cirrhosis
• Triglycerides \>1500 mg/dL (non-fasting) or \>1000 mg/dL (fasting) at screening.
• In subjects with partial lipodystrophy only, Hemoglobin A1c \>10% at screening.

Sponsors & Collaborators

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Lipodystrophy, Partial, Acquired; Insulin Resistance

Interventions

pegvisomant

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Rebecca J Brown, M.D.

  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Megan S Startzell, R.N.

CONTACT

(301) 402-6371; megan.startzell@nih.gov

Rebecca J Brown, M.D.

CONTACT

(301) 594-0609; brownrebecca@mail.nih.gov

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2022
• First Posted: July 22, 2022
• Study Start: January 23, 2023
• Primary Completion (Estimated): January 30, 2028
• Study Completion (Estimated): January 30, 2028
• Last Updated: May 1, 2026

Record last verified: 2026-04-29

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)